Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/18/2025

Combining Bupropion and Vortioxetine for Depression Treatment

Special Clinical Considerations

  • Bupropion may be particularly beneficial for patients with depression and comorbid smoking habits, as it is FDA-approved for smoking cessation, according to the National Comprehensive Cancer Network 1, 2
  • The combination of bupropion and vortioxetine should be avoided in patients with seizure disorders, due to bupropion's ability to lower the seizure threshold, as recommended by Gastroenterology 3, 2

Potential Risks and Side Effect Management

  • The second dose of bupropion should not be taken late in the day to minimize insomnia risk, and patients should be monitored for emergence of neuropsychiatric symptoms, especially in younger patients, as suggested by Gastroenterology 3, 4
  • Blood pressure monitoring is necessary, as bupropion can affect blood pressure, and vital signs should be monitored, according to Gastroenterology 4, 5

Dosing Considerations

  • Bupropion dosing should start with lower doses and gradually titrate to minimize side effects, with a maximum dose not exceeding 450 mg/day for immediate-release or 400 mg/day for sustained-release formulations, as recommended by Gastroenterology 3
  • Dose reduction is needed in moderate to severe hepatic or renal impairment, as suggested by Gastroenterology 4

Contraindications

  • The combination of bupropion and vortioxetine should be avoided in patients requiring opioid therapy, due to the naltrexone component, and in patients with uncontrolled hypertension, as recommended by Gastroenterology 4, 5
  • Patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs should also avoid this combination, according to Gastroenterology 4, 5

Monitoring Recommendations

  • Regular monitoring of blood pressure and heart rate is necessary, as well as monitoring for emergence of neuropsychiatric symptoms, especially in younger patients, as suggested by Gastroenterology 4, 5